Corvus Pharmaceuticals (CRVS) Change in Account Payables (2015 - 2026)

Corvus Pharmaceuticals' Change in Account Payables history runs 12 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 273.16% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $3.4 million (up 1225.91% YoY), while the FY2025 annual figure was -$91000.0, down 108.61% from the prior year.
• Change in Account Payables for Q1 2026 stood at $2.2 million, up from $517000.0 in the prior quarter.
• The five-year high for Change in Account Payables was $2.2 million in Q1 2026, with the low at -$2.3 million in Q4 2022.
• The 5-year median for Change in Account Payables is $210000.0 (2022), against an average of $184235.3.
• Peak annual rise in Change in Account Payables reached 561.87% in 2025, while the deepest fall reached 1616.67% in 2025.
• Corvus Pharmaceuticals' Change in Account Payables stood at -$2.3 million in 2022, then surged by 105.38% to $121000.0 in 2023, then jumped by 485.95% to $709000.0 in 2024, then dropped by 27.08% to $517000.0 in 2025, then surged by 326.69% to $2.2 million in 2026.
• Business Quant data shows CRVS's Change in Account Payables at $2.2 million in Q1 2026, $517000.0 in Q4 2025, and -$1.2 million in Q3 2025.